| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
REVIEW |
Department of Molecular & Integrative Physiology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
Correspondence should be addressed to T R Kumar; Email: tkumar{at}kumc.edu
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
subunit (
-GSU) and a hormone-specific ß subunit. Gonadotropins signal through G-protein coupled transmembrane receptors on the gonads and regulate gonadal growth, differentiation, and steroid production (Bousfield et al. 1994). LH and CG are structurally similar; human chorionic gonadotropin ß (hCGß) is characterized by the presence of a unique carboxy terminus peptide (CTP). This sequence is known to confer a longer half-life to CG in serum (Bousfield et al. 1994). Both hormones bind identical receptors and stimulate cAMP production in target cells. Distinct genes encode gonadotropin subunits; the subunits are synthesized as precursor proteins, processed, assembled and secreted via distinct mechanisms from pituitary gonadotropes or trophoblast cells (Pierce & Parsons 1981). Gene expression of the gonadotropin subunits is gender-specific and is co-ordinately regulated according to physiological demands by a number of autocrine, paracrine, and endocrine factors. Gonadotropin-releasing hormone (GnRH) is a hypothalamic decapeptide that binds to gonadotrope receptors and activates the pituitary gonadotropin subunit gene expression (Ruf et al. 2003). Members of transforming growth factor-ß superfamily including activins, inhibins, follistatin and bone morphogenetic proteins primarily regulate FSH homeostasis (Shimasaki et al. 2004). Understanding the biology of gonadotropins has many clinical implications with regard to fertility management and designing novel therapeutic strategies for many gonadal cancers.
-GSU knockout mice
|
|---|
|
|
|---|
-GSU, particularly during early pituitary development, Camper and her colleagues developed mice lacking
-GSU (Kendall et al. 1995). Since
-GSU is the common glycoprotein subunit for thyroid stimulating hormone (TSH), LH, and FSH, all three of the glycoprotein hormones were absent in these mutant mice. The mutant mice demonstrated profound hypothyroidism resulting in dwarfism. Embryological studies identified that thyroid development was arrested in late gestation and pituitary thyrotrope hyperplasia owing to a lack of thyroid hormone feedback was evident. Pituitary morphogenesis and GnRH neuron migration appeared normal in the absence of
-GSU. The mutant mice were hypogonadal; however, sexual differentiation and early development were unaffected in the absence of circulating gonadotropins. Homozygous male mice were infertile, had decreased testis size and undetectable serum testosterone levels. The accessory sex glands were atrophied consistent with lack of stimulation by testosterone. Histological analysis of the testes revealed normal fetal stage development, but at 8 weeks of age, smaller tubules were apparent, interstitial cells were rare, and spermatogenesis was blocked at the first meiotic division (Kendall et al. 1995). In female mutant mice, there was a failure in the opening of the vaginal orifice. These mice were infertile, demonstrated small ovaries and thin uteri and suppressed serum estradiol levels. Histological analysis of the ovary identified no antral follicles and corpora lutea confirming absence of estrous cycles (Kendall et al. 1995). These genetic studies with the
-GSU mice confirmed that early gonadal development is independent of gonadotropin function. | FSHß knockout mice |
|---|
|
|
|---|
-GSU knockout mice (described above) lack both of these gonadotropins in addition to TSH. These models are therefore disadvantageous to analyze the roles of only LH or FSH. To study the isolated deficiency of only FSH, we deleted most of the coding sequence of FSHß gene in ES cells and subsequently generated FSHß knockout mice from these targeted cells (Kumar et al. 1997). Since heterodimeric assembly is essential for in vivo biological activity, in the absence of the hormone-specific ß subunit, circulating FSH was absent in these mice. FSHß heterozygous mice were normal and fertile and did not demonstrate any overt phenotypes.
FSHß knockout male mice were fertile despite reduced testes size and volume of the seminiferous tubules. Although all stages of spermatogenesis appeared qualitatively normal, the epididymal sperm number and sperm motility were reduced by 75% and 40% respectively (Kumar et al. 1997). These studies confirmed species-specific differences in FSH regulation of spermatogenesis between mice and primates including humans immunized with various FSH-based vaccines (McLachlan et al. 2002, Moudgal & Sairam 1998, Moudgal et al. 1997, Plant & Marshall 2001). Stereological analysis confirmed ~30% reduction in the Sertoli cell number and the germ cell carrying capacity consistent with reduced testis size (~65%) in the mutant mice (Kumar et al. 2001, Wreford et al. 2001). The net number of Leydig cells per testis and serum testosterone in the mutants was not affected. Accordingly, the accessory sex glands appeared normal. It was also reported that the FSH-receptor demonstrates low-level constitutive activity in the absence of FSH ligand (Baker et al. 2003) and this explains somewhat milder phenotypes in FSHß knockout males compared with those in FSH-receptor knockout mice (see below). In contrast to apparently normal fertility in males, FSHß knockout females are infertile and demonstrated decreased ovary size and thin but mostly variable size uterine horns. Serum estradiol levels were not altered, but progesterone was reduced by 50% and LH levels were 23 fold elevated compared with age-matched controls. Ovarian histology indicated a preantral stage block in folliculogenesis with no corpora lutea. Primordial and multilayer preantral follicles appeared normal with normal granulosa, thecal cells and oocytes. Pregnant mare serum gonadotropin (PMSG)/hCG injections pharmacologically rescued FSHß knockout females suggesting the ovulatory competence is unaffected in the absence of FSH (Kumar et al. 1997). Further characterization of the adult ovarian mutant phenotype involved an analysis of gene expression in the absence of FSH. Consistent with normal thecal layer recruitment, P450 17
-hydroxylase and LH-R expression was localized in the mutant ovaries (Burns et al. 2001). Expression of many granulosa cell markers including P450 aromatase, serum/glucocorticoid kinase and inhibin/activin subunit mRNAs was reduced but no accumulation of LH-receptor mRNA in granulosa cells was evident. Cyclin D2 a downstream regulator of FSH action was marginally decreased without up-regulation of many cell cycle inhibitor mRNAs typically associated with cell cycle withdrawal at luteinization. Thus in the absence of FSH, although granulosa cells do not proliferate beyond the antral stage, they do not initiate programs of terminal differentiation observed during normal luteinization in wild type ovaries (Burns et al. 2001). These observations are consistent with the unaffected ovulatory competence of the FSHß knockout female mice; since the mutant female mice can be pharmacologically as well as genetically rescued resulting in normal luteinization of the follicles.
Hormonal control of somatic cell oocyte interactions during ovarian follicle development is poorly understood. To test the hypothesis that FSH regulates the ability of granulosa cells to make connections with the oocyte, FSHß knockout female mice were analyzed for transzonal projections (TZPs) between granulosa cells and oocytes in the ovaries. In FSHß knockout mice, similar to immature control mice, granulosa cells exhibit orientation towards the oocyte manifest by the elaboration of TZPs. In vivo FSH treatment of FSHß knockout mice results in alterations in somatic cell adhesion to the oocyte, enhances oocyte chromatin remodeling and apical centrosome positioning at sites of granulosazona contact (Combelles et al. 2004). FSH priming also decreases the density of TZPs and this coincides with changes in oocyte transcriptional activity and meiotic competence (Combelles et al. 2004). Thus, these studies have identified a critical role for FSH signaling in mediating the somatic cell oocyte interactions via regulation of TZPs and suggest that signaling from the oocyte acts as a checkpoint for oocyte development until hormone signaling in the somatic cells specifies further progression of the folliculogenesis.
Long-term consequences of the absence of FSH have been evaluated and these studies identified age-related uterine and ovarian hypertrophy pathologies in FSHß knockout females (Abel et al. 2003). At 1 year of age, uterine mass is significantly increased (more than 8 fold) in the majority of FSHß knockout females; however, the uteri are non-contractile and do not respond to electrical or pharmacological stimulation (Abel et al. 2003). The ovarian size is increased accompanied by hypertrophy of the interstitial tissue, with occasional presence of ovarian cysts and epithelial inclusions. Serum androgen levels are also slightly elevated (1.6 nmol/L compared with 1.0 nmol/L in the controls) in these mice. Ovariectomy resulted in decreased uterine mass and increased serum LH levels (Abel et al. 2003). These age-related phenotypes resemble the serous ovarian adenocarcinomas found in humans and suggest possible hormonal imbalance occurring as a result of defects in FSH-mediated signaling.
Genetic rescue of FSHß knockout mice
To confirm that the absence of FSH (as a result of the designed null mutation in the FSHß locus) alone contributed to the mutant phenotypes in FSHß knockout mice and to test whether interspecies glycoprotein hormone hybrids function in vivo, genetic rescue experiments were performed in two different ways (Kumar et al. 1998). In the first approach (type I rescue), a well characterized 10 kb of hFSHß transgene that contained all the appropriate regulatory elements for gonadotrope-specific expression and hormonal regulation was introduced in to the FSHß null background by a genetic intercross. The assumption was that the hFSHß transgene when expressed in the mouse pituitary environment in the absence of mouse FSHß, would recombine with the endogenous mouse
-GSU subunit and produce an interspecies hybrid FSH. In the second approach (type II rescue), two transgenes including the human
-GSU and hFSHß driven by MT promoter were similarly introduced into FSHß null background. In this line of mice hFSH is ectopically produced in low levels by multiple tissues. In both types of genetic rescue, the expression of hFSH transgenes in the FSHß null background, male mice were fertile; the testicular size, tubular volume and sperm number and motility were restored to values similar to those observed in wild type control mice. While the type I rescue female mice also were fertile and produced normal number of offspring when mated to wild type mice, only 20% of the type II rescue female mice were fertile and produced fewer pups than normal mice. These genetic rescue studies indicated that hFSHß transgene regulation and function in the mouse pituitary are indistinguishable from the endogenous mouse FSHß gene (Kumar et al. 1998).
| FSH-receptor knockout mice |
|---|
|
|
|---|
Male reproductive phenotypes in FORKO mice
FORKO males were fertile, displayed small testes and partial spermatogenic failure with defects in sperm viability and motility (Dierich et al. 1998). Although initially reported as fertile, later analyses revealed that FORKO males had a reduced fertility and a delay in puberty based on mating studies (Krishnamurthy et al. 2001a). Flow cytometric evaluation of germ cells revealed a significant increase in the percentage of spermatogonia and non-germ cells whereas there was a significant decrease in elongated spermatids. Defects in sperm head shape, chromatin condensation and chromatin remodeling were also observed (Krishnamurthy et al. 2000, Xing et al. 2003). During the prepubertal period, the expression of transition proteins and protamine-2 was greatly diminished leading to delayed spermatogenesis. Although round spermatids were abundant at this age, by 7 weeks only few tubules contained round spermatids. Mutant males also had decreased levels of testosterone and consequently a reduction in epididymis and seminal vesicle size (Dierich et al. 1998). To further investigate the reasons for low testosterone levels, Leydig cell function was analyzed in FORKO mice. LH-receptor density on Leydig cells and binding of LH to its receptor were normal. However, response to exogenous LH to produce testosterone was greatly reduced in mutants (Krishnamurthy et al. 2001b). These studies indicated that intercellular communication between Sertoli cells and Leydig cells was altered in the absence of FSH-receptor signaling. This may be an important issue in fertility management therapies aimed at inhibiting signaling through the FSH receptor.
Female reproductive phenotypes in FORKO mice
FORKO females had small ovaries and demonstrated a block in folliculogenesis before antral follicle formation, similar to FSHß knockout mice (Dierich et al. 1998). In adult mutant females, serum levels of LH and FSH were elevated and estrogens levels greatly reduced. Around 12 months of age, the majority of the mutant mice developed ovarian cysts and neoplasms including unilateral sex cord -stromal tumors (Danilovich et al. 2001). The incidence of these tumors was also observed in heterozygous mice around 15 months. The heterozygous mice initially had reduced fertility and they stopped breeding by 79 months. There was an accelerated loss of oocytes as a result of atresia and apoptosis that are typical characteristics of reproductive senescence (Balla et al. 2003, Danilovich & Sairam 2002, Yang et al. 2003b). These phenotypic changes were accompanied by circulating reproductive hormonal imbalance. Further molecular analysis of ovarian marker genes including those involved in oocyte and granulosa cell growth and development confirmed that the oocyte-somatic cell interactions were perturbed (Balla et al. 2003, Danilovich & Sairam 2002, Yang et al. 2003b). During this accelerated aging in heterozygous mice, prominent uterine pathology was also evident. In older heterozygous mice, the uterine weights were increased by 2-fold and occasionally uterine masses were observed in the right uterine horn. Increased angiogenesis, vascular abnormality and adenomyosis were also observed in the right uterine horn that contained pathological mass. Serum estrogen and progesterone were reduced whereas testosterone was elevated. Together, these studies suggest a haploinsufficiency phenotype due to gene dosage effect of the FSH-receptor (Danilovich et al. 2002).
Extra-gonadal phenotypes in FORKO mice
In addition to many ovarian defects due to chronic estrogen deficiency resembling those of human menopause, FORKO mice also demonstrated defects outside the ovary. Early loss of estrogen led to obesity and skeletal abnormalities including hunchback appearance (Danilovich et al. 2000). Heterozygous mice similarly showed these phenotypes coincident with their accelerated aging. Despite a marked estrogen insufficiency, the estrogen receptors remained functional since estrogen replacement therapy (by providing estradiol-17ß) reversed the accumulation of adipose tissue (Danilovich et al. 2000).
FORKO female mice also demonstrated many symptoms of menopause-associated hypertension in women. These include elevated blood pressure and a blunted response to angiotensin II induced vasoconstriction with significantly increased media-to-lumen ratio. The circulating levels of angiotensin II were decreased in FORKO female mice. Unlike in human hypertension, these studies suggested that although hypertension was observed in female FORKO mice, it was not mediated by angiotensin II in this menopause-associated mouse model (Javeshghani et al. 2003).
Estrogen is known to exert pleiotropic effects in the nervous system. The lack of estrogen and an observed estrogen-testosterone imbalance in the FORKO female mice provided a useful model to explore the neurological phenotypes dependent on estrogen function (Danilovich et al. 2003b). Choline acetyltransferase activity was decreased in many central cholinergic structures including striatum, hippocampus, cortex and dorsal root ganglia. Aberrations were also observed in the enzyme activities of mitogen-activated protein kinases in the hippocampus, dorsal root ganglion and sciatic nerves. Sensory and hippocampal ganglia contained hyper-phosphorylated neurofilament proteins that are important structural entities in these ganglia. The ability of neurite outgrowth of explanted ganglia was also decreased with and without estrogen treatment. Further studies identified that the size and amount of immunoreactive glial fibrillary acidic protein was increased in cortex and hippocampus and expression of estrogen
and ß receptors in amygdala was reduced in the FORKO mutants (Danilovich et al. 2003a). These changes were reflected in increased signs of anxiety in these mutant mice. Heterozygous mice showed similar neurological phenotypes of anxiety and degenerative changes in the nervous system (Danilovich et al. 2003a).
| LHß knockout mice |
|---|
|
|
|---|
LHß knockout males were infertile and demonstrated reduced size testes (by 75% compared with controls) and accessory glands, consistent with decreased serum (>90%) and intra-testicular (>95%) testosterone levels, and pituitary serum FSH levels were unaffected. Histological analysis of testes indicated insignificant interstitium containing very few and small size Leydig cells. Gene expression analyses confirmed an increase in fetal Leydig cell marker, thrombospondin-2, and reduction in many of the steroidogenic pathway enzymes and serum assays demonstrated increased levels of the androgen precursor, androstenedione, indicating the presence of mostly fetal and immature Leydig cells in the mutant testes (Ma et al. 2004).
To analyze the consequences of severely reduced testosterone on spermatogenesis, the mutant testes were analyzed histologically and expression of spermatogenesis markers was assessed. The mutant testes consist of spermatogonia, spermatocytes (meiotic cells) and round spermatids, but not late stage or elongated spermatids (Ma et al. 2004). Expression of histone H1-like linker protein, a late stage spermatid marker was suppressed in the mutant testes. Hence, FSH alone is not sufficient to promote full spermatogenesis in the absence of LH and/or testosterone. Since Sertoli cells are the major targets of androgen action within the testis, expression of Sertoli-specific markers was evaluated in the mutant testes. These studies identified that although expression of some markers (FSH receptor and inhibin
) was not affected, expression of inhibin ßA-and ßB-subunits and Anti-Müllerian hormone (AMH) was up-regulated (Ma et al. 2004). Thus, in LHß mutant mice phenocopy LH-receptor knockout mice (Lei et al. 2001, Zhang et al. 2001), the loss of LH leads to both somatic and spermatogenic cell defects, similarly seen in other models with a Sertoli cell-selective androgen receptor deletion. LHß mutant mice provide a useful model for further studying somatic-germ cell interactions in the testis.
LHß knockout females, similar to males were hypogonadal and infertile. Histological analysis of the ovaries indicated absence of healthy antral, preovulatory follicles and corpora lutea, confirming impaired estrous cycles. Primary and secondary follicles appeared normal, whereas many antral follicles were abnormal containing degenerating oocytes. Despite these defects in granulosa cells and oocytes, a prominent thecal layer was obvious in follicles at different stages of progression (Ma et al. 2004). These observations suggested that differentiation of thecal layer was not impaired in the absence of LH signaling. However, expression of various thecal cell markers including many steroidogenic enzymes was significantly reduced. Consequently, serum progesterone and estradiol levels were decreased by ~7075% and the mutant uteri were hypoplastic consisting of a thin endometrial layer (Ma et al. 2004). These ovarian phenotypes in LHß knockout mice are distinct from those of FSHß knockout mice and provide a genetic evidence for distinct roles of FSH and LH during folliculogenesis.
Pharmacological rescue of both male and female LHß knockout mice was achieved by short-term treatment of hCG. Testes and ovarian markers are up-regulated following hormone replacement of the mutants with hCG indicating that responsiveness to LH is not irreversibly lost in target cells in the absence of LH (Ma et al. 2004). Thus, LHß knockout mice serve as a useful model to study LH-and steroid-responsive genes and for identifying to what extent steroids mediate LH effects in target cells.
| LH-receptor knockout mice |
|---|
|
|
|---|
Male reproductive phenotypes in LuRKO mice
LuRKO male mice demonstrated a failure of testicular descent, and reduced size testes, accessory sex organs and external genitalia. The number and size of Leydig cells were also significantly reduced. Serum gonadotropins were elevated and intratesticular and serum testosterone was highly suppressed, whereas serum estradiol levels were moderately elevated (Lei et al. 2001, Zhang et al. 2001). Spermatogenesis was blocked at the round spermatid stage. Expression of androgen receptors, and FSH-receptors remained unchanged. In contrast, steroidogenic acute regulatory protein (StAR) and estrogen receptor-
were suppressed, and expression of estrogen receptor-ß was up-regulated. The expression of many Leydig cell-specific marker genes was gradually decreased from birth until adult stage when many of them were undetectable (Zhang et al. 2004). Testosterone replacement therapy partially restored the phenotypes and improved spermatogenesis nevertheless the mutant males remained infertile (Pakarainen et al. 2005b, Rao & Lei 2002). Similarly, some but not all of the epididymal phenotypes are restored to those observed in normal mice by androgen replacement therapy. More recent studies from Huhtaniemi group suggest that residual intra-testicular testosterone is sufficient to restore full spermatogenesis up to elongated spermatids (step 1316) in LuRKO males at 12 months of age (Zhang et al. 2003). Standard regimens of male contraception often include suppression of gonadotropin secretion leading to reduced but detectable levels of testosterone in only 60% of the treated men. Late-onset spermatogenesis recovery in LuRKO mice suggests that only total abolition of testicular androgen action will result in the consistent azoospermia necessary for effective male contraception (Zhang et al. 2003).
Reproductive defects in female LuRKO mice
Female LuRKO mice demonstrated small ovaries and thin uteri and the age of vaginal opening was delayed by almost a week compared with wild type controls. Histological analysis of the ovaries revealed antral but no preovualtory follicles or corporal lutea. Serum levels of estrogen and progesterone were suppressed (Lei et al. 2001, Zhang et al. 2001). Consistent with the size of the uterine horns, the thickness of all uterine layers decreased and only a few glands were present in the endometrium. Estradiol and progesterone replacement therapy of 4 week-old female LuRKO mice for 3 weeks resulted in normal vaginal development but the ovarian morphology did not change (Rao & Lei 2002). Although the uterus became thicker, the number of endometrial glands remained low. Ovarian steroid replacement did not restore fertility in LuRKO mice (Rao & Lei 2002).
From a comparative perspective, there are species-specific differences in gonadotropin regulation of the reproductive physiology. This is particularly striking when species including human, monkey and mice are compared. Unlike the former two, mice do not produce hCG and hence many aspects of early sexual differentiation are different between these species. Nevertheless, mice with null mutations in LHß and LH-R do phenocopy patients with inactivating mutations in the corresponding loci.
Extra-gonadal phenotypes in LuRKO mice
Extra-gonadal effects of LH/hCG are not well understood, despite many reports indicating that their receptors exist outside the reproductive tract. Two of the extra-gonadal phenotypes in LuRKO mice were characterized. These include an obese phenotype and defects in bone structure (Rao & Lei 2002, Yarram et al. 2003). The obese phenotype was evident early but became more pronounced around 1 year of age in both homozygous and heterozygous mutants. Histologically, the fat tissue contained hypertrophied adipocytes in these older mice (Rao & Lei 2002).
The bone phenotypes in LuRKO mice were those related to bone mineral density and bone histomorphometry. There was a decrease in bone mineral density in mutant males and all the bone morphometric parameters were reduced in LuRKO female mice. Although expression of the LH receptors on osteoblasts was confirmed by a variety of molecular techniques, these cells failed to bind 125I-hCG. In accordance with this, treatment of osteoblasts with hCG also failed to stimulate cAMP production (Yarram et al. 2003). Therefore, the defects in bone structure could be secondary to loss of steroids in the absence of LH signaling in LuRKO mice.
Controversy still exists with regard to extra-gonadal actions of LH/hCG. Conflicting evidence that either supports or contradicts such actions in mice has been reported. In one model, steroid replacement therapy failed to restore normal fertility and pregnancies in LuRKO female mice suggesting that extra-gonadal actions, perhaps mediated via the uterine receptors are important (Lei et al. 2001, Lin et al. 2005). More recent work has demonstrated redundancy of extra-gonadal LH action using another LuRKO model (Pakarainen et al. 2005a). In this model, normal fertility was restored in LuRKO mice after orthotopic transplantation of ovaries from wild-type mice indicating that absence of uterine LH receptors does not affect implantation and pregnancy (Pakarainen et al. 2005a). It is not clear what is the exact basis for this discrepancy between these two models. However, there are many reports indicating the extra-gonadal actions of LH/hCG in other species including human (Carlson et al. 2004, Eblen et al. 2001, Lin et al. 2003, Mishra et al. 2003, Rao et al. 2004a, Rao et al. 2004b, Rao 2001a, Rao et al. 2003, Toth et al. 2001, Yang et al. 2003a, Zygmunt et al. 2002). Whether these species differences truly reflect the fundamental differences in sexual differentiation and female reproductive physiology or due to variations in the experimental settings remains to be established. Future in vivo studies may provide more corroborative evidence for the extra-gonadal actions of LH/hCG.
| Mouse models for gonadotropin signaling and human reproductive disorders |
|---|
|
|
|---|
LHß knockout and LuRKO mice also phenocopy human patients with inactivating mutations in the LHß subunit or LH-receptor (Huhtaniemi 2000a, Themmen et al. 1998, Themmen & Huhtaniemi 2000). Two cases of loss of function mutations in the human LHß gene were also reported (Valdes-Socin et al. 2004, Weiss et al. 1992). In the first case, only immunoreactive LH was detectable; in both the cases, the mutation results in absence of bioactive LH in serum. Both patients were infertile hypogonadal men; normally masculinized at birth, had descended testes and testicular biopsy revealed absence of full spermatogenesis and mature Leydig cells (Valdes-Socin et al. 2004, Weiss et al. 1992). Although their circulating testosterone levels were low (<0.5 ng/ml), they were responsive to exogenous hCG stimulation. Long-term hCG treatment resulted in testicular enlargement, normal virilization and spermatogenesis (Valdes-Socin et al. 2004, Weiss et al. 1992). Phenotypes of women with similar inactivating LHß mutations are not known to date. Phenotypes of patients with partial versus complete inactivating LH receptor mutations vary. In the incomplete form, the phenotype is hypospadias (Misrahi et al. 1997) and the complete loss of LH receptor function in men leads to pseudohermaphroditism, i.e., complete sex reversal (Kremer et al. 1995). These patients have absent masculinization, and lack of testosterone consistent with absence of Leydig cells (Kremer et al. 1995). Interestingly, androgens must be produced from other sources or produced at very low levels from the testis, since accessory glands are present in these patients (Kremer et al. 1995). Women with inactivating LH receptor mutations have primary amenorrhea and normal primary and secondary sex characters and do not respond to hCG stimulation (Toledo et al. 1996). Ovarian histology closely resembles that of LHß knockout or LuRKO mice and demonstrates all stages of folliculogenesis excepting preovualtory follicles and corpora lutea (Toledo et al. 1996). Thus, the available gonadotropin ligand and receptor knockout mouse models closely but not completely resemble human patients with corresponding mutations. These mouse models will allow us to further analyze the roles of gonadotropins in gonad development, delineate the signaling pathways and identify downstream targets in the gonads of both sexes. These models will also eventually help to more precisely define the molecular basis for both common and the unique phenotypes observed in human patients.
| Conclusions and future directions |
|---|
|
|
|---|
Where are we heading in gonadotropin research? Our knowledge of GnRH signal relay and integration resulting in co-ordinately regulated expression of gonadotropins and their secretion from the pituitary is very limited. The availability of various existing cell lines (Kumar 2001, Mellon et al. 1991) and the ability to generate additional novel gonadotrope cell lines will be important for understanding this process. The ability to spatio-temporally control gene expression in mice may offer clues to roles of gonadotropins in distinct phases of gonad development (Gossen & Bujard 2002). More detailed analysis of the available mutant mouse models with enhanced or impaired gonadotropin action will provide answers regarding the signal transduction pathways downstream of LH and FSH in gonads of both sexes. The mutant mice also provide novel in vivo resources to analyze large-scale gene and protein expression profiles in the absence or over expression of gonadotropins. More recently, small interference RNA (siRNA) technology has become useful for abrogating gene function in various cell lines (Hannon & Rossi 2004, Karagiannis & El-Osta 2005, Paddison & Hannon 2002, Silva et al. 2004). In this approach, a desired mRNA encoding a protein of interest is eliminated by binding of a specific small RNA sequence that contains features such as stems and loops which selectively hybridizes and knockdown the target mRNA (Hannon & Rossi 2004, Karagiannis & El-Osta 2005, Paddison & Hannon 2002, Silva et al. 2004). Although more widely used for various in vitro studies, the application of the siRNA approach to temporally block RNA expression/function in vivo has not yet been routinely successful. It is anticipated that in the near future the siRNA approach will be used to identify various temporal events in gonadotropin action both in vitro and in vivo. Meanwhile other in vitro approaches continue to provide valuable structural information on gonadotropins that can be translated into explaining the in vivo physiology. For example, a tetrado-main glycoprotein hormone analog consisting of TSHß, FSHß, hCGß and
-subunits tandemly linked was expressed in vitro. This analog elicited multiple hormone activities in vivo and pharmacologically rescued FSHß knockout mice (Garcia-Campayo et al. 2002, Garcia-Campayo et al. 2005). It may prove useful for studying thyroid regulation of the fertility status in vivo during normal and abnormal reproductive cycles. Similarly, the in vitro characterized yoked hCG-receptor single chain protein was expressed in gonads of transgenic mice to create a familial precocious puberty mouse model (Meehan et al. 2005). More recently, LuRKO mice have been used as recipients for transplantation of Leydig cell progenitors and it was demonstrated that these transplanted cells produced testosterone de novo in the mutant testis (Lo et al. 2004). This study exemplifies the use of mouse models for formulating therapies for human male infertility cases in the future.
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Abel MH, Huhtaniemi I, Pakarinen P, Kumar TR & Charlton HM 2003 Age-related uterine and ovarian hypertrophy in FSH receptor knockout and FSHbeta subunit knockout mice. Reproduction 125 165173.[Abstract]
Abel MH, Wootton AN, Wilkins V, Huhtaniemi I, Knight PG & Charlton HM 2000 The effect of a null mutation in the follicle-stimulating hormone receptor gene on mouse reproduction. Endocrinology 141 17951803.
Aittomaki K, Herva R, Stenman UH, Juntunen K, Ylostalo P, Hovatta O & de la Chapelle A 1996 Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. Journal of Clinical Endocrinology and Metabolism 81 37223726.[Abstract]
Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila EM, Lehvaslaiho H & Engel AR et al. 1995 Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82 959968.[CrossRef][ISI][Medline]
Baker PJ, Pakarinen P, Huhtaniemi IT, Abel MH, Charlton HM, Kumar TR & OShaughnessy PJ 2003 Failure of normal Leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSHbeta-deficient mice: role for constitutive FSH receptor activity. Endocrinology 144 138145.
Balla A, Danilovich N, Yang Y & Sairam MR 2003 Dynamics of ovarian development in the FORKO immature mouse: structural and functional implications for ovarian reserve. Biology of Reproduction 69 12811293.
Beau I, Touraine P, Meduri G, Gougeon A, Desroches A, Matuchansky C, Milgrom E, Kuttenn F & Misrahi M 1998 A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. Journal of Clinical Investigation 102 13521359.[ISI][Medline]
Bousfield GR, Perry WM & Ward DN 1994 Gonadotropins: chemistry and biosynthesis. In The Physiology of Reproduction, pp 17491792. Eds E Knobil & JD Neill. New York: Raven Press.
Burns KH, Yan C, Kumar TR & Matzuk MM 2001 Analysis of ovarian gene expression in follicle-stimulating hormone beta knockout mice. Endocrinology 142 27422751.
Carlson HE, Kane P, Lei ZM, Li X & Rao CV 2004 Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. Journal of Clinical Endocrinology and Metabolism 89 41194123.
Combelles CM, Carabatsos MJ, Kumar TR, Matzuk MM & Albertini DF 2004 Hormonal control of somatic cell oocyte interactions during ovarian follicle development. Molecular Reproduction and Development 69 347355.[CrossRef][ISI][Medline]
Danilovich N & Sairam MR 2002 Haploinsufficiency of the follicle-stimulating hormone receptor accelerates oocyte loss inducing early reproductive senescence and biological aging in mice. Biology of Reproduction 67 361369.
Danilovich N, Roy I & Sairam MR 2001 Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology 142 36733684.
Danilovich N, Roy I & Sairam MR 2002 Emergence of uterine pathology during accelerated biological aging in FSH receptor-haploinsufficient mice. Endocrinology 143 36183627.
Danilovich N, Sairam MR & Maysinger D 2003a The menopausal mouse: a new neural paradigm of a distressing human condition. Neuroreport 14 16171622.[CrossRef][ISI][Medline]
Danilovich N, Harada N, Sairam MR & Maysinger D 2003b Age-related neurodegenerative changes in the central nervous system of estrogen-deficient follitropin receptor knockout mice. Experimental Neurology 183 559572.[CrossRef][ISI][Medline]
Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H & Sairam MR 2000 Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 141 42954308.
Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M & Sassone-Corsi P 1998 Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. PNAS 95 1361213617.
Eblen A, Bao S, Lei ZM, Nakajima ST & Rao CV 2001 The presence of functional luteinizing hormone/chorionic gonadotropin receptors in human sperm. Journal of Clinical Endocrinology and Metabolism 86 26432648.
Garcia-Campayo V, Kumar TR & Boime I 2002 Thyrotropin, follitropin, and chorionic gonadotropin expressed as a single multi-functional unit reveal remarkable permissiveness in receptor-ligand interactions. Endocrinology 143 37733778.
Garcia-Campayo V, Boime I, Ma X, Daphna-Iken D & Kumar TR 2005 A single-chain tetradomain glycoprotein hormone analog elicits multiple hormone activities in vivo. Biology of Reproduction 72 301308.
Gossen M & Bujard H 2002 Studying gene function in eukaryotes by conditional gene inactivation. Annual Reviews in Genetics 36 153173.
Griswold MD, Heckert L & Linder C 1995 The molecular biology of the FSH receptor. Journal of Steroid Biochemistry and Molecular Biology 53 215218.[CrossRef][ISI][Medline]
Hannon GJ & Rossi JJ 2004 Unlocking the potential of the human genome with RNA interference. Nature 431 371378.[CrossRef][Medline]
Heckert LL & Griswold MD 2002 The expression of the follicle-stimulating hormone receptor in spermatogenesis. Recent Progress in Hormone Research 57 129148.
Huhtaniemi I 1995 Molecular aspects of the ontogeny of the pituitary-gonadal axis. Reproduction, Fertility and Development 7 10251035.[CrossRef][Medline]
Huhtaniemi I 2000a Activating and inactivating hormone receptor mutations. Hormonal Research 53 916.
Huhtaniemi I 2000b The Parkes lecture. Mutations of gonadotrophin and gonadotrophin receptor genes: what do they teach us about reproductive physiology. Journal of Reproduction and Fertility 119 173186.[Abstract]
Huhtaniemi I, Jiang M, Nilsson C & Pettersson K 1999 Mutations and polymorphisms in gonadotropin genes. Molecular and Cellular Endocrinology 151 8994.[CrossRef][ISI][Medline]
Huhtaniemi IT 2002 The role of mutations affecting gonadotrophin secretion and action in disorders of pubertal development. Best Practice & Research. Clinical Endocrinology & Metabolism 16 123138.
Javeshghani D, Touyz RM, Sairam MR, Virdis A, Neves MF & Schiffrin EL 2003 Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension 42 761767.
Karagiannis TC & El-Osta A 2005 RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Therapy.
Kendall SK, Samuelson LC, Saunders TL, Wood RI & Camper SA 1995 Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice. Genes & Development 9 20072019.
Kremer H, Kraaij R, Toledo SP, Post M, Fridman JB, Hayashida CY, van Reen M, Milgrom E, Ropers HH & Mariman E et al. 1995 Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nature Genetics 9 160164.[CrossRef][ISI][Medline]
Krishnamurthy H, Danilovich N, Morales CR & Sairam MR 2000 Qualitative and quantitative decline in spermatogenesis of the follicle-stimulating hormone receptor knockout (FORKO) mouse. Biology of Reproduction 62 11461159.
Krishnamurthy H, Babu PS, Morales CR & Sairam MR 2001a Delay in sexual maturity of the follicle-stimulating hormone receptor knockout male mouse. Biology of Reproduction 65 522531.
Krishnamurthy H, Kats R, Danilovich N, Javeshghani D & Sairam MR 2001b Intercellular communication between Sertoli cells and Leydig cells in the absence of follicle-stimulating hormone-receptor signaling. Biology of Reproduction 65 12011207.
Kumar TR 2001 Neuroendocrine cell-specific immortalization using transgenic approaches. In Transgenics in Endocrinology, pp 425466. Eds MM Matzuk, CE Brown, TR Kumar, Totowa: Humana Press.
Kumar TR & Matzuk MM 2000 Gene knockout models to study the hypothalamus-pituitary-gonadal axis. In Gene engineering and molecular models in endocrinology, Ed. MA Shupnik. Totowa: Humana Press.
Kumar TR, Low MJ & Matzuk MM 1998 Genetic rescue of follicle-stimulating hormone beta-deficient mice. Endocrinology 139 32893295.
Kumar TR, Wang Y, Lu N & Matzuk MM 1997 Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nature Genetics 15 201204.[CrossRef][ISI][Medline]
Kumar TR, Varani S, Wreford NG, Telfer NM, de Kretser DM & Matzuk MM 2001 Male reproductive phenotypes in double mutant mice lacking both FSHbeta and activin receptor IIA. Endocrinology 142 35123518.
Layman LC, Porto AL, Xie J, da Motta LA, da Motta LD, Weiser W & Sluss PM 2002 FSH beta gene mutations in a female with partial breast development and a male sibling with normal puberty and azoospermia. Journal of Clinical Endocrinology and Metabolism 87 37023707.
Lei ZM, Mishra S, Zou W, Xu B, Foltz M, Li X & Rao CV 2001 Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. Molecular Endocrinology 15 184200.
Lin DX, Lei ZM, Li X & Rao Ch V 2005 Targeted disruption of LH receptor gene revealed the importance of uterine LH signaling. Molecular and Cellular Endocrinology 234 105116.[CrossRef][ISI][Medline]
Lin PC, Li X, Lei ZM & Rao Ch V 2003 Human cervix contains functional luteinizing hormone/human chorionic gonadotropin receptors. Journal of Clinical Endocrinology and Metabolism 88 34093414.
Lindstedt G, Nystrom E, Matthews C, Ernest I, Janson PO & Chatterjee K 1998 Follitropin (FSH) deficiency in an infertile male due to FSHbeta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clinical Chemistry and Laboratory Medicine 36 663665.[CrossRef][ISI][Medline]
Lo KC, Lei Z, Rao Ch V, Beck J & Lamb DJ 2004 De novo testosterone production in luteinizing hormone receptor knockout mice after transplantation of leydig stem cells. Endocrinology 145 40114015.
Ma X, Dong Y, Matzuk MM & Kumar TR 2004 Targeted disruption of luteinizing hormone beta-subunit leads to hypogonadism, defects in gonadal steroidogenesis, and infertility. PNAS 101 1729417299.
Markkula M & Huhtaniemi I 1996 Transgenic animals and gonadotrophins. Reviews of Reproduction 1 97106.
Mason AJ, Hayflick JS, Zoeller RT, Young WS 3rd, Phillips HS, Nikolics K & Seeburg PH 1986a A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse. Science 234 13661371.
Mason AJ, Pitts SL, Nikolics K, Szonyi E, Wilcox JN, Seeburg PH & Stewart TA 1986b The hypogonadal mouse: reproductive functions restored by gene therapy. Science 234 13721378.
Mason AJ, Pitts SL, Nikolics K, Szonyi E, Wilcox JN, Seeburg PH & Stewart TA 1987 Gonadal development and gametogenesis in the hypogonadal mouse are restored by gene transfer. Annals of the New York Academy of Sciences 513 1626.[Abstract]
Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeschini G, Benedetti A & Chatterjee VK 1993 Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nature Genetics 5 8386.[CrossRef][ISI][Medline]
McLachlan RI, ODonnell L, Meachem SJ, Stanton PG, de Kretser DM, Pratis K & Robertson DM 2002 Identification of specific sites of hormonal regulation in spermatogenesis in rats, monkeys, and man. Recent Progress in Hormone Research 57 149179.
Meehan TP, Harmon BG, Overcast ME, Yu KK, Camper SA, Puett D & Narayan P 2005 Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin-lutropin receptor complex. Journal of Molecular Endocrinology 34 489503.
Mellon PL, Windle JJ & Weiner RI 1991 Immortalization of neuroendocrine cells by targeted oncogenesis. Recent Progress in Hormone Research 47 6993; 9366 discussion.
Mishra S, Lei ZM & Rao Ch V 2003 A novel role of luteinizing hormone in the embryo development in cocultures. Biology of Reproduction 68 14551462.
Misrahi M, Meduri G, Pissard S, Bouvattier C, Beau I, Loosfelt H, Jolivet A, Rappaport R, Milgrom E & Bougneres P 1997 Comparison of immunocytochemical and molecular features with the phenotype in a case of incomplete male pseudohermaphroditism associated with a mutation of the luteinizing hormone receptor. Journal of Clinical Endocrinology and Metabolism 82 21592165.
Moudgal NR & Sairam MR 1998 Is there a true requirement for follicle stimulating hormone in promoting spermatogenesis and fertility in primates? Human Reproduction 13 916919.
Moudgal NR, Jeyakumar M, Krishnamurthy HN, Sridhar S, Krishnamurthy H & Martin F 1997 Development of male contraceptive vaccinea perspective. Human Reproduction Update 3 335346.
Paddison PJ & Hannon GJ 2002 RNA interference: the new somatic cell genetics? Cancer Cell 2 1723.[CrossRef][ISI][Medline]
Pakarainen T, Zhang FP, Poutanen M & Huhtaniemi I 2005a Fertility in luteinizing hormone receptor-knockout mice after wild-type ovary transplantation demonstrates redundancy of extragonadal luteinizing hormone action. Journal of Clinical Investigation 115 18621868.[CrossRef][ISI][Medline]
Pakarainen T, Zhang FP, Makela S, Poutanen M & Huhtaniemi I 2005b Testosterone replacement therapy induces spermatogenesis and partially restores fertility in luteinizing hormone receptor knockout mice. Endocrinology 146 596606.
Phillip M, Arbelle JE, Segev Y & Parvari R 1998 Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. New England Journal of Medicine 338 17291732.
Pierce JG & Parsons TF 1981 Glycoprotein hormones: structure and function. Annual Reviews of Biochemistry 50 465495.
Plant TM & Marshall GR 2001 The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocrine Reviews 22 764786.
Rao CV, Zhou XL & Lei ZM 2004a Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells. Biology of Reproduction 71 579587.
Rao CV, Li X, Manna SK, Lei ZM & Aggarwal BB 2004b Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation. Journal of Biological Chemistry 279 2550325510.
Rao CV 2001a An overview of the past, present, and future of non-gonadal LH/hCG actions in reproductive biology and medicine. Seminars in Reproductive Medicine 19 717.[CrossRef][ISI][Medline]
Rao CV 2001b Multiple novel roles of luteinizing hormone. Fertility and Sterility 76 10971100.[CrossRef][ISI][Medline]
Rao CV & Lei ZM 2002 Consequences of targeted inactivation of LH receptors. Molecular and Cellular Endocrinology 187 5767.[CrossRef][ISI][Medline]
Rao SC, Li X, Rao Ch V & Magnuson DS 2003 Human chorionic gonadotropin/luteinizing hormone receptor expression in the adult rat spinal cord. Neuroscience Letters 336 135138.[CrossRef][ISI][Medline]
Ruf F, Fink MY & Sealfon SC 2003 Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Frontiers in Neuroendocrinology 24 181199.[CrossRef]